DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2007/0209082 A1 Lih Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2007/0209082 A1 Lih Et Al US 20070209082A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0209082 A1 Lih et al. (43) Pub. Date: Sep. 6, 2007 (54) TXR1 AND ENHANCED TAXANE Publication Classification SENSTIVITY BASED ON THE MODULATION OF A PATHWAY MEDIATED (51) Int. Cl. THEREBY AOIK 67/027 (2006.01) CI2O I/68 (2006.01) (76) Inventors: Chih Jian Lih, Palo Alto, CA (US); A6IR 48/00 (2006.01) Stanley N. Cohen, Stanford, CA (US) A6II 3L/337 (2006.01) CI2P 2/06 (2006.01) C07K I4/705 (2006.01) Correspondence Address: C07K 6/30 (2006.01) BOZICEVIC, FIELD & FRANCIS LLP (52) U.S. Cl. .............................. 800/14: 514/449; 514/44; 1900 UNIVERSITY AVENUE 435/6: 435/69. 1; 435/325; 435/320.1; SUTE 200 530/350; 530/388.8; 536/23.5 EAST PALO ALTO, CA 94.303 (US) (57) ABSTRACT (21) Appl. No.: 11/357,728 Methods and compositions for enhancing taxane sensitivity are provided. Aspects of the Subject methods include admin (22) Filed: Feb. 16, 2006 istering to a subject a tXrl pathway modulatory agent in Related U.S. Application Data conjunction with a taxane. Also provided are tXrl polypep tides and nucleic acids encoding the same. The Subject (60) Provisional application No. 60/654,343, filed on Feb. methods and compositions find use in a variety of different 17, 2005. applications. Patent Application Publication Sep. 6, 2007 Sheet 1 of 7 US 2007/0209082 A1 Fig 1. A. 5 dTR is s dTR 3 dTR 3 tr downstream u gene crp Tc RP B. 120 e-M2182tTA 60 40 M2182TA M2182TATc Cone 18 Cone 18+Tc CHO M2182tTA Clone 18 -Tc +c -Tc +Tc B-tubulin (25X, 154bp) Extes (25X, 22Obp) Osas sessie etPisaray be it (25x,B -actin 12Obp) Patent Application Publication Sep. 6, 2007 Sheet 2 of 7 US 2007/0209082 A1 Fig. 2 A. GSV D. M2182tTA-- Cone-r- 18 integration S. -TC +Tc - c. --Tc -a-tubulin 52121713 Chro Tosome 21254 - - Txt 1 12q13 Pre-intune Seut B. E. MWNPNAGOPGENPPPNGCPGGSNPAHPPPINPPFPPGPCPPPPGAPHG NPAFPPGGPPHPvPQPGYPGCQPLGPYPPPYPPPAPGIPPVNPLAPGMVG PAVIVDKKMOKKMKKAHKKMHKHQKHHKYHKHGKHSSSSSSSSSSDSD C. M2182tTA ClOne 18 anti-TxT txr1 (1.2kb) b-actin txr1 (20X 156bp) Patent Application Publication Sep. 6, 2007 Sheet 3 of 7 US 2007/0209082 A1 Fig. 3 Clone 18 M2182tTA E. No taxo 2.5M taxo F. 508 0.6 g 0.4 > 2 0.2 on S1 SI2 Control C. G. g -le-Clone 18 control s -e-M2182TAvcontrol s --Core 18S -a-M2182TASI1 -o-Clone 18S2 o -o-M2182tTAVS2 d O S o r 2 s s s s as o a O 100 taxol (nM) D a & H. s e eS of (-tubulin o-tubulin Tx 1 Tx1 Patent Application Publication Sep. 6, 2007 Sheet 4 of 7 US 2007/0209082 A1 Fig. 4 A. B. taxol (nM) 4. 5 10 Cone R1 -TC +TC X C. tit.1.3.1.-1 100 8) 6 OnM 2.5M 3M 4nM SnM 10nM 120 too OnM 2.5M 3M 4M SnM 10nM Patent Application Publication Sep. 6, 2007 Sheet 5 of 7 US 2007/0209082 A1 Fig.5 A. A382A Chris -ic ce 18- ckne 3 ic C. M2182ttA core r2 he attaplest TXRA WS vs ws WS -- -- N28A a M8A T. cyre 8 wic M28TA . tc. le -- - +c 1 2 3 1 2 3 2 3 1 2 3 Ma82TA cine Ra heatTAlpStixRA D. 2. s tr1 g -- trff TSP-1 sansiliityS; Q G B. 3. M2182TA Clone18 -TC +TC -Tc +TC . W. Cockkinos contellation coefficient r1 vs TSP-1 -0.86 tor ws taxo -0.83 TSP-1 vs taxo 0.67 Patent Application Publication Sep. 6, 2007 Sheet 6 of 7 US 2007/0209082 A1 80 60 Control AD ET VB VC EpoB x B. D. taxol. OnM SM 1.4 t. Tan. -------- TSP-1 Quvrn OS ... e. itsP1 is uom TSP1 w >< 1.2 7.5ugm, O So 8 > th- is 0.8 - X 06 2 0.8 TSP. O 804 3 0.4 Ougm ><>< 0.2 D.2 SZNZOO taxonM taxoSM 0. Control AD ET VB VC EpoB E. taxo 10nM Control taxo 10nM TSP-17.5ug/ml TSP-17.5ug/ml Control STSP-1 ... taxol: onM 1M 2nM 3nM 4nM 5nM in an ISP. Patent Application Publication Sep. 6, 2007 Sheet 7 of 7 US 2007/0209082 A1 Fig 7. Clone 18 M2182tTA o to a o o to p o y CD47 ; 20 0. - AaT-6 to 150pm --ABT-5 to room orpae T-12sum : 20 s 1 so 4N1K 250M US 2007/0209082 A1 Sep. 6, 2007 TXR1 AND ENHANCED TAXANE SENSTIVITY sents the meant-SD from eight replicates: (FIG. 1C) Tc effect BASED ON THE MODULATION OF A PATHWAY on taxol resistance in clone 18. Equal numbers of M2182tTA MEDIATED THEREBY and clone 18 cells were seeded and treated with the indicated concentration of taxane in the presence (+Tc) or absence CROSS-REFERENCE TO RELATED (-Tc) of tetracycline (1 lug/ml) for colony forming assays. APPLICATIONS Cell colonies were stained by 0.5% crystal violet. (FIG. 1D) Tc effect on taxol uptake in clone 18. Equal numbers of the 0001 Pursuant to 35 U.S.C. S 119 (e), this application indicated cell lines were seeded, incubated with H. taxol. claims priority to the filing date of U.S. Provisional Patent washed, and Subjected to Scintillation counting for measur Application Ser. No. 60/654,343 filed on Feb. 17, 2005; the ing the rate of uptake. Chinese hamster ovary (CHO) cells, disclosure of which application is herein incorporated by which are known to contain high efflux activity were used as reference. controls (Parekh & Simpkins, Biochem Pharmacol (1996) 51:301–311). Each histogram represents the meaniSD of BACKGROUND four independent experiments. (FIG. 1E) Gene expression of 0002 Taxane is a family of major chemotherapeutic B-tubulin isoforms. Poly(A) RNAs extracted from indicated agents that have anti-neoplastic effects against a wide spec cell lines were used as templates to quantitatively analyze trum of human cancers. Despite a dramatic response of expression of B-tubulins I and III by RT-PCR. The cycle Susceptible tumors to initial treatment with taxanes, the number and product size are indicated. Subsequent development of resistance to these drugs has 0006 FIGS. 2A-2F. Cloning, Gene Expression, and proved to be a major limitation to long-term use of these Localization of tXr1 (FIG. 2A) Schematic diagram of GSV agents as anticancer drugs. Two well-studied mechanisms integration site and tXrl gene structure. GSV provirus inte associated with such resistance are: (1) mutations in ATP grated (inverse triangle, arrowhead indicates the direction of dependant B-glycoproteins that lead to exclusion of taxanes transcription from the Tc-regulated promoter) at chromo and a variety of other drugs from cells (i.e. transporter Some locus 12q13 (horizontal line). The genomic nucleotide related multidrug resistance; MDR-1); and (2) mutations coordinate for the integration site and coordinates for the that affect the binding of taxanes to microtubules. However, start and end of tXrl transcripts are indicated below the line it has long been apparent that still other undefined mecha in bold type. Four exons of tXrl gene are shown as Solid nisms are also implicated in taxane resistance. boxes and the cDNA nucleotide coordinates for the start and end of each exon are italicized. The codons initiating and SUMMARY terminating translation (start and stop, respectively) are 0003 Methods and compositions for enhancing taxane indicated.(FIG. 2B) TXrl protein sequence deduced from sensitivity are provided. Aspects of the subject methods cDNA sequence. The peptide used as antigen for raising include administering to a Subject a tXrl pathway modula antibodies is underlined. (FIG. 2C) Effect of Tc on tXr1 tory agent in conjunction with a taxane. Also provided are transcript in clone 18. Northern blot (top panel), poly(A) tXrl polypeptides and nucleic acids encoding the same. The RNA extracted from indicated cells/conditions were frac Subject methods and compositions find use in a variety of tionated by electrophoresis, transferred onto filter, and different applications. probed with radioactively labeled tXr1 and B-actin cDNA fragments. The size of the tXrl transcript is indicated. The BRIEF DESCRIPTION OF THE FIGURES same RNAs were used as template for RT-PCR analysis (bottom panel), the cycle number and product size of the 0004 The file of this patent contains at least one drawing RT-PCR product are indicated. (FIG. 2D) Effect of Tc on executed in color. Copies of this patent with color draw Txrl protein in clone 18. Cell lysates extracted from indi ing(s) will be provided by the Patent and Trademark Office cated cells/conditions were Subjected to immunoblotting upon request and payment of the necessary fee. analysis and probed with anti-TXrl and anti-C-tubulin anti 0005 FIGS. 1A to 1E. Identification and Characterization bodies. (FIG. 2E) Intracellular localization of Txrl. HeLa of Taxol Resistant Cell Clones. (FIG. 1A) Structure of cells were immunofluorescence stained with preimmune integrated provirus derived from retroviral gene search serum (left, upper) or anti-Txrl polyclonal antibodies (left, vector (GSV). 3'dLTR or 5'dLTR (open boxes), designate lower). Chinese hamster ovary cells transfected with pCMV defective retroviral long terminal repeats lacking promoter EGFPN1 (right, upper) or pEGFPTXrl (right, lower) were and enhancer sequences required for virion production; SA, stained with DAPI (blue). Fluorescent images were obtained splicing acceptor site from adenovirus; neo, reporter gene by confocal microscopy. (FIG. 2F) Multiple tissue Northern encodes resistance to G418 (arrow in box indicates the blot. A filter (Clontech) containing RNA extracted from the sense direction of transcription; the broken arrow at the top indicated tissues was probed with radioactively labeled tXr1 indicates the location and 5' to 3’ direction of the primer used and B-actin cDNA fragments.
Load more

Recommended publications
  • Re-Visiting Hypersensitivity Reactions to Taxanes: a Comprehensive Review
    Clinic Rev Allerg Immunol DOI 10.1007/s12016-014-8416-0 Re-visiting Hypersensitivity Reactions to Taxanes: A Comprehensive Review Matthieu Picard & Mariana C. Castells # Springer Science+Business Media New York 2014 Abstract Taxanes (a class of chemotherapeutic agents) Keywords Taxane . Paclitaxel . Taxol . Docetaxel . are an important cause of hypersensitivity reactions Taxotere . Nab-paclitaxel . Abraxane . Cabazitaxel . (HSRs) in cancer patients. During the last decade, the Chemotherapy . Hypersensitivity . Allergy . Skin test . development of rapid drug desensitization has been key Desensitization . Challenge . Diagnosis . Review . IgE . to allow patients with HSRs to taxanes to be safely re- Complement . Mechanism treated although the mechanisms of these HSRs are not fully understood. Earlier studies suggested that solvents, such as Cremophor EL used to solubilize paclitaxel, Introduction were responsible for HSRs through complement activa- tion, but recent findings have raised the possibility that Hypersensitivity reactions (HSRs) to chemotherapy are in- some of these HSRs are IgE-mediated. Taxane skin creasingly common and represent an important impediment testing, which identifies patients with an IgE-mediated to the care of cancer patients as they may entail serious sensitivity, appears as a promising diagnostic and risk consequences and prevent patients from being treated with stratification tool in the management of patients with the most efficacious agent against their cancer [1]. During the HSRs to taxanes. The management of patients following last decade, different groups have developed rapid drug de- a HSR involves risk stratification and re-exposure could sensitization (RDD) protocols that allow the safe re- be performed either through rapid drug desensitization introduction of a chemotherapeutic agent to which a patient or graded challenge based on the severity of the initial is allergic, and their use have recently been endorsed by the HSR and the skin test result.
    [Show full text]
  • BC Cancer Benefit Drug List September 2021
    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
    [Show full text]
  • Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
    Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H.
    [Show full text]
  • Filed by Cell Therapeutics, Inc. Pursuant to Rule 425 Under The
    Filed by Cell Therapeutics, Inc. Pursuant to Rule 425 under the Securities Act of 1933 And deemed filed pursuant Rule 14a-12 Of the Securities Exchange Act of 1934 Subject Company: Cell Therapeutics, Inc. Commission File No.: 001-12465 The following is a transcript of a presentation given by Cell Therapeutics, Inc. at its annual meeting of shareholders, held on June 20, 2003. Moderator: Jim Bianco Operator: Good day everyone and welcome to the Cell Therapeutics annual shareholder meeting. As a reminder, this call is being recorded. We’ll soon be going live to Seattle where the call will begin shortly. Please stand by. Jim Bianco: Welcome. My name is Jim Bianco. I’m the President and CEO of Cell Therapeutics. Welcome to our 2003 shareholders meeting. Our business meeting agenda today is to approve the minutes, elect the directors, and approve the equity incentive plan as well as the amendment to the employees stock purchase plan, and ratify the selection of E&Y as independent auditors. Mike Kennedy, the Secretary of the company, will act as secretary of this meeting, and George Pabst has been appointed inspector of elections to examine and count proxies and ballots. At the conclusion of the business portion of today’s meeting, members of management will present highlights from the past year and outline some of our future milestones and objectives for the next 12 to 18 months. At this time, I’d like to call the meeting to order. Let me begin by introducing our directors who are present today and let me start by saying that Dr.
    [Show full text]
  • Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: from Discovery to Implementation
    G C A T T A C G G C A T genes Review Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation Reka Varnai 1,2, Leena M. Koskinen 3, Laura E. Mäntylä 3, Istvan Szabo 4,5, Liesel M. FitzGerald 6 and Csilla Sipeky 3,* 1 Department of Primary Health Care, University of Pécs, Rákóczi u 2, H-7623 Pécs, Hungary 2 Faculty of Health Sciences, Doctoral School of Health Sciences, University of Pécs, Vörösmarty u 4, H-7621 Pécs, Hungary 3 Institute of Biomedicine, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland 4 Institute of Sport Sciences and Physical Education, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 5 Faculty of Sciences, Doctoral School of Biology and Sportbiology, University of Pécs, Ifjúság útja 6, H-7624 Pécs, Hungary 6 Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania 7000, Australia * Correspondence: csilla.sipeky@utu.fi Received: 17 June 2019; Accepted: 5 August 2019; Published: 8 August 2019 Abstract: Prostate cancer is the fifth leading cause of male cancer death worldwide. Although docetaxel chemotherapy has been used for more than fifteen years to treat metastatic castration resistant prostate cancer, the high inter-individual variability of treatment efficacy and toxicity is still not well understood. Since prostate cancer has a high heritability, inherited biomarkers of the genomic signature may be appropriate tools to guide treatment. In this review, we provide an extensive overview and discuss the current state of the art of pharmacogenomic biomarkers modulating docetaxel treatment of prostate cancer. This includes (1) research studies with a focus on germline genomic biomarkers, (2) clinical trials including a range of genetic signatures, and (3) their implementation in treatment guidelines.
    [Show full text]
  • Exosomes and Breast Cancer Drug Resistance Xingli Dong1,2, Xupeng Bai 2,3,Jieni2,3,Haozhang 4,Weiduan5, Peter Graham2,3 Andyongli 2,3,6
    Dong et al. Cell Death and Disease (2020) 11:987 https://doi.org/10.1038/s41419-020-03189-z Cell Death & Disease REVIEW ARTICLE Open Access Exosomes and breast cancer drug resistance Xingli Dong1,2, Xupeng Bai 2,3,JieNi2,3,HaoZhang 4,WeiDuan5, Peter Graham2,3 andYongLi 2,3,6 Abstract Drug resistance is a daunting challenge in the treatment of breast cancer (BC). Exosomes, as intercellular communicative vectors in the tumor microenvironment, play an important role in BC progression. With the in-depth understanding of tumor heterogeneity, an emerging role of exosomes in drug resistance has attracted extensive attention. The functional proteins or non-coding RNAs contained in exosomes secreted from tumor and stromal cells mediate drug resistance by regulating drug efflux and metabolism, pro-survival signaling, epithelial–mesenchymal transition, stem-like property, and tumor microenvironmental remodeling. In this review, we summarize the underlying associations between exosomes and drug resistance of BC and discuss the unique biogenesis of exosomes, the change of exosome cargo, and the pattern of release by BC cells in response to drug treatment. Moreover, we propose exosome as a candidate biomarker in predicting and monitoring the therapeutic drug response of BC and as a potential target or carrier to reverse the drug resistance of BC. ● Facts Tumor-derived exosomes mediate enhanced EMT and stem-like property of drug-resistant BC. ● ● Tumor-derived exosomes mediate the chemoresistance TME-derived exosomes mediate the tumor of BC by reducing the intracellular accumulation of microenvironmental remodeling that favors the drug resistance of BC. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; chemotherapeutic drugs and delivering functional ● cargos that activate pro-survival signaling and The exosome is proposed as a candidate biomarker in unchecked cell cycle progression.
    [Show full text]
  • W O 2 11/ 28571Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date / 10 March 2011 (10.03.2011) W O 2 1 1/ 28 57 1 A l (51) International Patent Classification: (74) Agents: UDAL, Robert, P., Ph. D. et al; Morgan, Lewis A 43/02 (2006.01) & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103 (US). (21) International Application Number: PCT/US20 10/046627 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 25 August 2010 (25.08.2010) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (26) Publication Language: English KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (30) Priority Data: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 61/238,787 1 September 2009 (01 .09.2009) US NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (71) Applicant (for all designated States except US): TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. TAPESTRY PHARMACEUTICALS, INC. [US/US]; 6304 Spine Road, Unit A, Boulder, CO 80301 (US). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (75) Inventors/ Applicants (for US only): MCCHESNEY, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, James, D.
    [Show full text]
  • Treatment of Taxane Acute Pain Syndrome (TAPS) in Cancer Patients Receiving Taxane-Based Chemotherapy—A Systematic Review
    Support Care Cancer (2016) 24:1583–1594 DOI 10.1007/s00520-015-2941-0 ORIGINAL ARTICLE Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy—a systematic review Ricardo Fernandes1 & Sasha Mazzarello2 & Habeeb Majeed3 & Stephanie Smith 2 & Risa Shorr4 & Brian Hutton5 & Mohammed FK Ibrahim1 & Carmel Jacobs1 & Michael Ong1 & Mark Clemons1,2,6 Received: 21 May 2015 /Accepted: 3 September 2015 /Published online: 19 September 2015 # Springer-Verlag Berlin Heidelberg 2015 Abstract randomized open-label trials 76 patients), and one was a ret- Background Taxane acute pain syndrome (TAPS) is charac- rospective study (10 patients). The agents investigated includ- terized by myalgias and arthralgias starting 1–3 days and last- ed gabapentin, amifostine, glutathione, and glutamine. Study ing 5–7 days after taxane-based chemotherapy. Despite nega- sizes ranged from 10 to 185 patients. Given the heterogeneity tively impacting patient’s quality of life, little is known about of study designs, a narrative synthesis of results was per- the optimal TAPS management. A systematic review of treat- formed. Neither glutathione (QoL, p = 0.30, no 95 % CI re- ment strategies for TAPS across all tumor sites was performed. ported) nor glutamine (mean improvement in average pain Methods Embase, Ovid MEDLINE(R), and the Cochrane was 0.8 in both treatment arms, p = 0.84, no 95 % CI reported) Central Register of Controlled Trials were searched from were superior to placebo. Response to amifostine (pain re- 1946 to October 2014 for trials reporting the effectiveness of sponse) and gabapentin (reduction in taxane-induced arthral- different treatments of TAPS in cancer patients receiving gias and myalgias) was 36 % (95 % CI, 16–61 %) and 90 % taxane-based chemotherapy.
    [Show full text]
  • CTI Corporate Presentation
    20062006 InvestInvest NorthwestNorthwest conferenceconference JamesJames A.A. Bianco,Bianco, M.D.M.D. PresidentPresident andand CEOCEO C E L L T H E R A P E U T I C S, I N C. (N A S D A Q : C T I C) ForwardForward LookingLooking StatementStatement This presentation contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The forward-looking statements contained in this presentation include statements about future financial and operating results, and risks and uncertainties that could affect CTI’s product and products under development. These statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. Therefore, actual outcomes and results may differ materially from what is expressed herein. In any forward-looking statement in which CTI expresses an expectation or belief as to future results, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. The following factors, among others, could cause actual results
    [Show full text]
  • Section B Changed Classes/Guidelines Final
    EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2019 Section B Changed Classes/Guidelines Final Version Date of issue: 24th December 2018 1 A3 FUNCTIONAL GASTRO-INTESTINAL DISORDER DRUGS R2003 A3A PLAIN ANTISPASMODICS AND ANTICHOLINERGICS R1993 Includes all plain synthetic and natural antispasmodics and anticholinergics. A3B Out of use; can be reused. A3C ANTISPASMODIC/ATARACTIC COMBINATIONS This group includes combinations with tranquillisers, meprobamate and/or barbiturates except when they are indicated for disorders of the autonomic nervous system and neurasthenia, in which case they are classified in N5B4. A3D ANTISPASMODIC/ANALGESIC COMBINATIONS R1997 This group includes combinations with analgesics. Products also containing either tranquillisers or barbiturates and analgesics to be also classified in this group. Antispasmodics indicated exclusively for dysmenorrhoea are classified in G2X1. A3E ANTISPASMODICS COMBINED WITH OTHER PRODUCTS r2011 Includes all other combinations not specified in A3C, A3D and A3F. Combinations of antispasmodics and antacids are classified in A2A3; antispasmodics with antiulcerants are classified in A2B9. Combinations of antispasmodics with antiflatulents are classified here. A3F GASTROPROKINETICS r2013 This group includes products used for dyspepsia and gastro-oesophageal reflux. Compounds included are: alizapride, bromopride, cisapride, clebopride, cinitapride, domperidone, levosulpiride, metoclopramide, trimebutine. Prucalopride is classified in A6A9. Combinations of gastroprokinetics with other substances
    [Show full text]
  • Homoharringtonine: a Pharmacognosy Success Story by Dr
    THE AMERICAN SOCIETY OF PHARMACOGNOSY The ASP Newsletter Volume 48, Issue 4 Homoharringtonine: A Pharmacognosy Success Story By Dr. Richard Powell n October 26, 2012, the United States Food and Drug Administration (FDA) approved Syn- ribo® (omacetaxine mepesuccinate) to treat adults with chronic myelogenous leukemia O(CML), a blood and bone marrow disease. Approxi- mately 5,430 people will be diagnosed with CML in 2012, according to the NIH. Synribo is intended to be used in patients whose cancer progressed af- ter treatment with at least two drugs from a class called tyrosine kinase inhibitors (TKIs), also used to treat CML. My work on this drug began almost five decades ago, and I originally gave Synribo the common name homoharringtonine in 1970. The road to approval of Synribo for treatment of leukemia in the United States has been a long and torturous one, but in the beginning it ran closely parallel to that of the discovery of the well-known antitumor drug Taxol®. Cepha- lotaxus harringtonia (Cephalotaxaceae) and other Cephalotaxus species (commonly called plum yews) are mostly small trees native to Japan and mainland China. Cephalotaxus harringtonia had been intro- duced as an ornamental but gained little popularity in the United States prior to 1960. I began working at The Northern Regional Re- search Center, United States Department of Ag- riculture (USDA), Agricultural Research Service (ARS), Peoria, Illinois, in the summer of 1963. The position involved chemical analysis of seeds of pre- viously uninvestigated plants, determining struc- Above left: Homoharringtonine from China, 1mg/ml. continued on page 3 Dr. Richard Powell working out the structure of homoharringtonine, 1980.
    [Show full text]
  • REVIEW Taxanes: Promising Anti-Cancer Drugs
    Taxanes: Promising Anti-Cancer Drugs REVIEW Taxanes: Promising Anti-Cancer Drugs Nilufer Jasmine Selimah Fauzee1, Zhi Dong2, Ya-lan Wang1* Abstract Taxanes are amongst the most promising antitumor agents available at hand today, of increasing importance in Asia given that cancer is now one of the major public health problems which needs to be dealt urgently for the benefit of affected patients. Several ongoing experimental and clinical trials have supported the fact that even with their side effects and poor solubilities, taxanes are still the first lines of treatment chosen for breast, ovary, lung and other metastatic cancers. Prolonging the life of cancer patients is the main aim of all researchers, scientists, pharmaceutical companies and clinicians; therefore this review emphasizes the mechanisms of action of taxanes and how they can play an important role in palliative treatment if not applied for curative purposes, hence being considered a boon for cancer management. Keywords: Taxanes - Taxol - Taxotere - cancer chemotherapy Asian Pacific J Cancer Prev, 12, 837-851 Introduction is of tremendous eagerness in the cancer field. So, here we have tried to underline their mechanism of action Taxanes are the most recently solicited chemotherapeutic under the rationale of their use and current development drugs of our era. During the past decades, these unique in oncology. hydrophobic mitotic inhibitors have been thoroughly investigated through numerous experimental and clinical Taxanes - Their Saga trials which have brought hope in breast, ovarian, lung, prostate (Tannock et al., 2004; Khan et al., 2003), Taxanes are remarkable cytotoxic diterpenes derived pancreas, gastric (Cosimo et al., 2003; Roth and Ajani, from natural products as described above.
    [Show full text]